ClinicalTrials.Veeva

Menu

EXPAREL® for Pain After Tonsillectomy

Mayo Clinic logo

Mayo Clinic

Status and phase

Completed
Phase 4

Conditions

Post-operative Pain
Tonsillitis
Tonsillectomy

Treatments

Drug: Liposomal Bupivacaine

Study type

Interventional

Funder types

Other

Identifiers

NCT02444533
14-007071

Details and patient eligibility

About

The purpose of this study is to determine whether liposomal bupivacaine (long acting injectable anesthetic) provides greater post operative pain relief compared to the standard post operative pain regiment for tonsillectomy patients.

Full description

Subjects will be screened in the clinic when being evaluated for indications for tonsillectomy. Once the decision to proceed with tonsillectomy is made, the patient will be given the information on the study, provided time to review the information and interested patients will be consented.

There will be two stages in the study. The first will be the operative stage, which includes the injection during the operation. The second stage is the patient participation stage. During this stage, the patient records the amount of oral pain medication usage, oral intake after their procedure, in addition to their pain scores. These scores are recorded and brought back (or mailed in) to the clinic for collection during the follow up visit, approximately 1 month later (patients will keep records for two weeks). The patients will be freed from participation in the study after the one month visit.

Enrollment

39 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Diagnosis of recurrent tonsillitis or bilateral tonsillar hypertrophy requiring bilateral tonsillectomy
  • Willing and able to understand and provide written informed consent

Exclusion criteria

  • Known pregnancy
  • Women who are currently nursing a child
  • History of coagulopathy; such as hemophilia or Von Willebrand disease, or any congenital or acquired bleeding disorder
  • Use of anticoagulation medication during the study, i.e. aspirin, Coumadin, Plavix, or medications similar in class to these medications will exclude the patient from participation
  • Inability to provide informed consent (patients under guardianship)
  • Known hypersensitivity to local anesthetics
  • History of cardiac disease; such as current impaired cardiovascular function, past history of myocardial infarction, congenital heart disease, current cardiac symptoms, i.e. angina, shortness of breath, or chest pain as determined by history or review of the medical record.
  • History of complex pulmonary disease; such as uncontrolled asthma, chronic obstructive pulmonary disease (COPD), or interstitial lung disease as determined by history or review of the medical record.
  • Impaired renal function as documented in the medical record in the last 3 months with a serum creatinine greater than 1.2 mg/dL or glomerular filtration rate < 60 mL/min/body surface area (BSA) as determined by history or review of the medical record.
  • History of or current hepatic disease as documented by liver function test abnormality in the last 3 months as determined by history or review of the medical record.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

39 participants in 2 patient groups

Liposomal Bupivacaine
Active Comparator group
Description:
Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
Treatment:
Drug: Liposomal Bupivacaine
No treatment
No Intervention group
Description:
Patient will not be given any medications in the tonsillar fossae after tonsillectomy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems